INVEX Therapeutics Ltd (IXC) - Net Assets
Based on the latest financial reports, INVEX Therapeutics Ltd (IXC) has net assets worth AU$4.55 Million AUD (≈ $3.22 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$4.72 Million ≈ $3.34 Million USD) and total liabilities (AU$176.49K ≈ $124.88K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read IXC total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$4.55 Million |
| % of Total Assets | 96.26% |
| Annual Growth Rate | -12.18% |
| 5-Year Change | -83.64% |
| 10-Year Change | N/A |
| Growth Volatility | 57.6 |
INVEX Therapeutics Ltd - Net Assets Trend (2019–2025)
This chart illustrates how INVEX Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Also explore IXC asset base for the complete picture of this company's asset base.
Annual Net Assets for INVEX Therapeutics Ltd (2019–2025)
The table below shows the annual net assets of INVEX Therapeutics Ltd from 2019 to 2025. For live valuation and market cap data, see IXC stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$5.25 Million ≈ $3.71 Million |
-7.76% |
| 2024-06-30 | AU$5.69 Million ≈ $4.02 Million |
-73.21% |
| 2023-06-30 | AU$21.23 Million ≈ $15.02 Million |
-25.45% |
| 2022-06-30 | AU$28.48 Million ≈ $20.15 Million |
-11.22% |
| 2021-06-30 | AU$32.08 Million ≈ $22.70 Million |
+31.46% |
| 2020-06-30 | AU$24.40 Million ≈ $17.27 Million |
+113.34% |
| 2019-06-30 | AU$11.44 Million ≈ $8.09 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to INVEX Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1946586300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$22.41 Million | 427.12% |
| Other Comprehensive Income | AU$2.53 Million | 48.27% |
| Other Components | AU$1.00 | 0.00% |
| Total Equity | AU$5.25 Million | 100.00% |
INVEX Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of INVEX Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Farlim Group (Malaysia) Bhd
KLSE:6041
|
$6.92 Million |
|
DY6 Metals Ltd
AU:DY6
|
$6.92 Million |
|
Castelbajac Co. Ltd
KQ:308100
|
$6.93 Million |
|
Cell Impact AB
ST:CI
|
$6.93 Million |
|
Mountain Province Diamonds Inc
TO:MPVD
|
$6.91 Million |
|
Advent Wireless Inc
V:AWI
|
$6.91 Million |
|
Edgewater Wireless Systems Inc
V:YFI
|
$6.90 Million |
|
Sumber Mas Konstruksi Tbk PT
JK:SMKM
|
$6.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INVEX Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,688,421 to 5,247,254, a change of -441,167 (-7.8%).
- Net loss of 476,868 reduced equity.
- Other comprehensive income increased equity by 35,700.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-476.87K | -9.09% |
| Other Comprehensive Income | AU$35.70K | +0.68% |
| Other Changes | AU$1.00 | +0.0% |
| Total Change | AU$- | -7.76% |
Book Value vs Market Value Analysis
This analysis compares INVEX Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.88x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.63x to 1.88x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-06-30 | AU$0.21 | AU$0.13 | x |
| 2020-06-30 | AU$0.43 | AU$0.13 | x |
| 2021-06-30 | AU$0.43 | AU$0.13 | x |
| 2022-06-30 | AU$0.38 | AU$0.13 | x |
| 2023-06-30 | AU$0.28 | AU$0.13 | x |
| 2024-06-30 | AU$0.08 | AU$0.13 | x |
| 2025-06-30 | AU$0.07 | AU$0.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently INVEX Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -208.16%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.04x
- Recent ROE (-9.09%) is above the historical average (-15.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -2.03% | -178461.54% | 0.00x | 1.08x | AU$-1.38 Million |
| 2020 | -13.77% | -2027.93% | 0.01x | 1.08x | AU$-5.80 Million |
| 2021 | -7.12% | -1438.38% | 0.00x | 1.02x | AU$-5.49 Million |
| 2022 | -13.88% | -2168.99% | 0.01x | 1.04x | AU$-6.80 Million |
| 2023 | -36.50% | -1688.14% | 0.02x | 1.07x | AU$-9.87 Million |
| 2024 | -28.87% | -135.48% | 0.20x | 1.08x | AU$-2.21 Million |
| 2025 | -9.09% | -208.16% | 0.04x | 1.04x | AU$-1.00 Million |
Industry Comparison
This section compares INVEX Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $9,810,720
- Average return on equity (ROE) among peers: -71.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INVEX Therapeutics Ltd (IXC) | AU$4.55 Million | -2.03% | 0.04x | $6.91 Million |
| Adalta Ltd (1AD) | $3.70 Million | -162.25% | 0.87x | $6.50 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $-1.33 Million | 0.00% | 0.00x | $20.04 Million |
| ACRUX Ltd (ACR) | $12.85 Million | -73.71% | 0.44x | $3.20 Million |
| Actinogen Medical Ltd (ACW) | $21.74 Million | -43.69% | 0.07x | $105.70 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $15.45 Million |
| Arovella Therapeutics Ltd (ALA) | $11.03 Million | -40.87% | 0.23x | $58.08 Million |
| Anatara Lifesciences Ltd (ANR) | $924.54K | -218.83% | 0.54x | $1.57 Million |
| Alterity Therapeutics Ltd (ATH) | $20.73 Million | -6.40% | 0.01x | $76.95 Million |
| Amplia Therapeutics Ltd (ATX) | $11.23 Million | -30.16% | 0.02x | $50.82 Million |
| Avecho Biotechnology Ltd (AVE) | $3.27 Million | -95.48% | 0.53x | $28.59 Million |
About INVEX Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II… Read more